The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches

被引:9
作者
Kizaki, Masahiro [1 ]
Tabayashi, Takayuki [1 ]
机构
[1] Saitama Med Univ, Saitama Med Ctr, Dept Hematol, 1981 Kamoda, Kawagoe, Saitama 3508550, Japan
关键词
multiple myeloma; cytokines; signaling pathway; molecular-targeted therapy;
D O I
10.3960/jslrt.56.20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of novel agents, such as bortezomib, thalidomide, and lenalidomide, into daily practice has dramatically improved clinical outcomes and prolonged survival of patients with multiple myeloma (MM). However, despite these advanced clinical benefits, MM remains an incurable hematological malignancy. Therefore, development of new agents and novel therapeutic strategies is urgently needed. Recent advances toward understanding the mechanism of myeloma cell growth and drug resistance in the bone marrow milieu have provided clues for the development of next-generation agents aimed at improving patient outcomes. In this review article, we discuss new possible agents for the treatment of MM based on recent advances in the understanding of signaling pathways in myeloma cells. [J Clin Exp Hematop 56(1):20-27, 2016]
引用
收藏
页码:20 / 27
页数:8
相关论文
共 58 条
[11]   Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma [J].
Farag, Sherif S. ;
Zhang, Shuhong ;
Jansak, Buffy S. ;
Wang, Xiaojing ;
Kraut, Eric ;
Chan, Kenneth ;
Dancey, Janet E. ;
Grever, Michael R. .
LEUKEMIA RESEARCH, 2009, 33 (11) :1475-1480
[12]   Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients [J].
Gay, Francesca ;
Larocca, Alessandra ;
Wijermans, Pierre ;
Cavallo, Federica ;
Rossi, Davide ;
Schaafsma, Ron ;
Genuardi, Mariella ;
Romano, Alessandra ;
Liberati, Anna Marina ;
Siniscalchi, Agostina ;
Petrucci, Maria T. ;
Nozzoli, Chiara ;
Patriarca, Francesca ;
Offidani, Massimo ;
Ria, Roberto ;
Omede, Paola ;
Bruno, Benedetto ;
Passera, Roberto ;
Musto, Pellegrino ;
Boccadoro, Mario ;
Sonneveld, Pieter ;
Palumbo, Antonio .
BLOOD, 2011, 117 (11) :3025-3031
[13]   Targeting apoptosis pathways in cancer therapy [J].
Ghobrial, IM ;
Witzig, TE ;
Adjei, AA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (03) :178-194
[14]   Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010 [J].
Harousseau, Jean-Luc .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (06) :424-442
[15]   B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? [J].
Hengeveld, P. J. ;
Kersten, M. J. .
BLOOD CANCER JOURNAL, 2015, 5 :e282-e282
[16]   Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma [J].
Hideshima, T ;
Nakamura, N ;
Chauhan, D ;
Anderson, KC .
ONCOGENE, 2001, 20 (42) :5991-6000
[17]   Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets [J].
Hideshima, Teru ;
Mitsiades, Constantine ;
Tonon, Giovanni ;
Richardson, Paul G. ;
Anderson, Kenneth C. .
NATURE REVIEWS CANCER, 2007, 7 (08) :585-598
[18]   Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells [J].
Hideshima, Teru ;
Catley, Laurence ;
Yasui, Hiroshi ;
Ishitsuka, Kenji ;
Raje, Noopur ;
Mitsiades, Constantine ;
Podar, Klaus ;
Munshi, Nikhil C. ;
Chauhan, Dharminder ;
Richardson, Paul G. ;
Anderson, Kenneth C. .
BLOOD, 2006, 107 (10) :4053-4062
[19]   Histone deacetylase inhibitors in the treatment for multiple myeloma [J].
Hideshima, Teru ;
Anderson, Kenneth C. .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (03) :324-332
[20]   Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells [J].
Hideshima, Teru ;
Ikeda, Hiroshi ;
Chauhan, Dharminder ;
Okawa, Yutaka ;
Raje, Noopur ;
Podar, Klaus ;
Mitsiades, Constantine ;
Munshi, Nikhil C. ;
Richardson, Paul G. ;
Carrasco, Ruben D. ;
Anderson, Kenneth C. .
BLOOD, 2009, 114 (05) :1046-1052